|
|
Blood, 15 September 2004, Vol. 104, No. 6, pp. 1671-1678.
Prepublished online as a Blood First Edition Paper on May 27, 2004; DOI 10.1182/blood-2004-03-1115.
Previous Article | Next Article 
Submitted March 24, 2004
Accepted May 10, 2004
Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure
Jichun Chen*, Karen Lipovsky, Felicia M Ellison, Rodrigo T Calado, and Neal S Young
Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
* Corresponding author; email: chenji{at}nhlbi.nih.gov.
Infusion of parental lymph node (LN) cells into sublethally-irradiated hybrid F1 recipients created a murine model for bone marrow (BM) failure. Affected animals developed fetal pancytopenia within 2-3 weeks accompanied by BM oligo-clonal T cell infiltration and severe marrow hypoplasia: approximately 10-fold declines in total BM cellularity, 15-fold declines in BM Lin-Sca1+c-Kit+ cells, 100-fold declines in spleen colony-forming units, and 100-fold declines in hematopoietic progenitor/stem cells as estimated by irradiation protection in vivo. LN cells of both H2b/b and H2d/d haplotypes are effectors. Serum gamma-interferon concentration increased 2-3-fold.Marrow cells were severely apoptotic with high proportion of Fas+ and annexin V+ cells. Co-transplantation of 5 x 105 BM cells from clinically affected donors and 106 BM cells from H2 identical normal mice could not rescue lethally-irradiated recipients and recipients had significantly lower cellularity in peripheral blood and BM; the cell mixtures also failed to produce a stromal feeder layer to support marrow cell growth in vitro. Pathogenic T cells from BM failure donors appear capable of destroying hematopoietic progenitor, stem, and stromal cells from fully compatible normal donors as innocent bystanders. This effect can be partially abrogated by anti- -interferon antibody.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. J. Stotler, B. Eghtesad, E. Hsi, and B. Silver
Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept
Blood,
May 21, 2009;
113(21):
5365 - 5366.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. O. Omokaro, M. J. Desierto, M. A. Eckhaus, F. M. Ellison, J. Chen, and N. S. Young
Lymphocytes with Aberrant Expression of Fas or Fas Ligand Attenuate Immune Bone Marrow Failure in a Mouse Model
J. Immunol.,
March 15, 2009;
182(6):
3414 - 3422.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-S. Delisle, L. Gaboury, M.-P. Belanger, E. Tasse, H. Yagita, and C. Perreault
Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-{gamma} receptor-deficient hosts
Blood,
September 1, 2008;
112(5):
2111 - 2119.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Verbinnen, A. D. Billiau, J. Vermeiren, G. Galicia, D. M. A. Bullens, L. Boon, P. Cadot, G. Hens, C. Dewolf-Peeters, S. W. Van Gool, et al.
Contribution of Regulatory T Cells and Effector T Cell Deletion in Tolerance Induction by Costimulation Blockadel
J. Immunol.,
July 15, 2008;
181(2):
1034 - 1042.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Chen, F. M. Ellison, M. A. Eckhaus, A. L. Smith, K. Keyvanfar, R. T. Calado, and N. S. Young
Minor Antigen H60-Mediated Aplastic Anemia Is Ameliorated by Immunosuppression and the Infusion of Regulatory T Cells
J. Immunol.,
April 1, 2007;
178(7):
4159 - 4168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Young, R. T. Calado, and P. Scheinberg
Current concepts in the pathophysiology and treatment of aplastic anemia
Blood,
October 15, 2006;
108(8):
2509 - 2519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Young
Pathophysiologic Mechanisms in Acquired Aplastic Anemia
Hematology,
January 1, 2006;
2006(1):
72 - 77.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Chen and N. S. Young
A Murine Model of Bone Marrow Failure Mediated by Disparity in Minor Histocompatibility Antigens.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
132 - 132.
[Abstract]
|
 |
|

|
 |

|
 |
 
M. P. Westerman, A. Pizzey, J. Hirshman, M. Cerino, A. Eze, A. Lawrie, G. Purdie, I. Mackie, and J. Porter
Hydroxyurea Treated Sickle Disorders Demonstrate Decreased Plasma Hb, Red Cell Vesicles and Thrombolysis.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
2322 - 2322.
[Abstract]
|
 |
|

|
 |

|
 |
 
A. M. Risitano
New Challenges to Developing Animal Models for Human Immune-Mediated Marrow Failure
Clin. Med. Res.,
May 1, 2005;
3(2):
63 - 64.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Chen
Animal Models for Acquired Bone Marrow Failure Syndromes
Clin. Med. Res.,
May 1, 2005;
3(2):
102 - 108.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|